HCPCS Level II code J7209 describes an injection of recombinant Factor VIII (antihemophilic factor, brand Nuwiq) billed per 1 International Unit; the service is for intravenous infusion of clotting factor used in management of hemophilia A and is typically administered in an outpatient infusion center or hospital outpatient department or, when appropriate, in an ambulatory clinic or home infusion setting.

For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only), Antibody-Drug Conjugates.